ContraFect

ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia

Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation

YONKERS, N.Y., June  15, 2020  (GLOBE NEWSWIRE) --   ContraFect Corporation    (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the appointment of Lishan Aklog, M.D. to the Company’s board of directors (Board). Dr. Aklog is Co-Founder, Chairman and Chief Executive Officer of PAVmed Inc. (Nasdaq: PAVM). He specialized in cardiothoracic surgery to begin his medical career. 

ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors

YONKERS, N.Y., May  21, 2020  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritten public offering of 11,797,752 shares of its common stock and related warrants to purchase 8,848,314 shares of common stock with an exercise price of $4.90 per share, in exchange for consideration equating to $4.45 for one share of common stock and a warrant to purchase 0.75 shares of common stock. The gross proceeds from the public offering will be approximately $52.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraFect. All shares in the public offering are to be sold by ContraFect. 

ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants

YONKERS, N.Y., May  21, 2020  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase additional shares of its common stock.  The public offering is subject to market conditions, and there can be no assurance as to whether or when the public offering may be completed, or the actual size or terms of the public offering. All of the securities in the public offering are to be sold by ContraFect.   

ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants

YONKERS, N.Y., May  15, 2020  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results for the first quarter ended March 31, 2020.

ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update

Abstracts highlight the advancement of three new antibacterial modalities: novel native lysins, engineered lysins and amurin peptides Abstracts highlight the advancement of three new antibacterial modalities: novel native lysins, engineered lysins and amurin peptides

ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book

YONKERS, N.Y., March  30, 2020  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research, will virtually chair the opening day of the 22nd Annual Superbugs & Superdrugs 2020 Conference. Dr. Cassino will also virtually present the Company’s anti-infective portfolio and platform technology of DLAs in her talk, “Exploring Direct Lytic Agents (DLAs) and their potential as a successful disruptive anti-infective technology.”

ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference

YONKERS, N.Y., March  18, 2020  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results for the fourth quarter and full year ended December 31, 2019.

ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and  Provides Business Update

YONKERS, N.Y., Feb.  24, 2020  (GLOBE NEWSWIRE) --   ContraFect Corporation    (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to exebacase for the treatment of MRSA bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients.

ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis

ContraFect: A Game-Changing Treatment For The Superbug MRSA

YONKERS, N.Y., Feb.  04, 2020  (GLOBE NEWSWIRE) --   ContraFect Corporation    (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced a one-for-ten reverse stock split of its shares of common stock. Stockholders of ContraFect approved an amendment to the Company’s Certificate of Incorporation to effect the reverse stock split at a Special Meeting of Stockholders held on January 31, 2020. The reverse stock split is intended to give ContraFect greater flexibility in considering and planning for future potential business needs and to increase the per share trading price of the Company’s common stock to satisfy the $1.00 minimum price requirement for continued listing on The Nasdaq Capital Market. At approximately 5:45 p.m., Eastern Time, on February 3, 2020, the Company filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to effect the reverse stock split with the Secretary of State of the State of Delaware. The reverse stock split became effective immediately upon the filing of the Certificate of Amendment. At the opening of trading on February 4, 2020, ContraFect expects its common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market under the symbol “CFRX” and under a new CUSIP number 212326300.

ContraFect Announces One-for-Ten Reverse Stock Split

YONKERS, N.Y., Feb.  03, 2020  (GLOBE NEWSWIRE) --   ContraFect Corporation    (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Jane E. Ambler, Ph.D. has been appointed as Vice President of Clinical Microbiology. Dr. Ambler will lead the the Company’s microbiology efforts in support of the pivotal Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) superiority study of exebacase in patients with Staphylococcus aureus bacteremia, including right-sided endocarditis and in advancement of the Company’s pipeline of DLAs. Dr. Ambler has over 25 years of experience in clinical laboratory microbiology and antimicrobial drug development, and she has numerous book and journal publications.

ContraFect Appoints Jane E. Ambler, Ph.D.

ContraFect Corporation Is A Differentiated Infectious Disease Pick For 2020

YONKERS, N.Y., Jan.  10, 2020  (GLOBE NEWSWIRE) --   ContraFect Corporation    (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the first patient has been dosed in the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis.

ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

Superiority Trial to Confirm Significantly Improved Clinical Outcomes with Exebacase Added to Antibiotics versus Antibiotics alone to treat Methicillin-Resistant Staph aureus (MRSA) Bacteremia  Superiority Trial to Confirm Significantly Improved Clinical Outcomes with Exebacase Added to Antibiotics versus Antibiotics alone to treat Methicillin-Resistant Staph aureus (MRSA) Bacteremia

ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

Pre-Clinical Data Demonstrate Efficacy and Tolerability as a Potential Targeted Therapeutic for serious infections caused by multi-drug resistant P. aeruginosa Pre-Clinical Data Demonstrate Efficacy and Tolerability as a Potential Targeted Therapeutic for serious infections caused by multi-drug resistant P. aeruginosa

ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa

YONKERS, N.Y., Dec.  17, 2019  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritten public offering of 25,650,000 shares of its common stock at a public offering price of $0.39 per share. The gross proceeds from the offering will be approximately $10 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraFect.  All shares in the offering are to be sold by ContraFect. 

ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock

YONKERS, N.Y., Dec.  09, 2019  (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced that it has commenced an underwritten public offering of shares of its common stock.  ContraFect also announced that Pfizer Inc. has entered into a stock purchase agreement with ContraFect pursuant to which Pfizer has agreed to purchase up to $3 million of shares of ContraFect’s common stock, at a price per share equal to the price per share in the proposed public offering, in a separate private placement transaction that is expected to close concurrently with the public offering. The public offering is subject to market conditions and the private placement is contingent upon the closing of the public offering, and there can be no assurance as to whether or when the public offering and private placement may be completed, or the actual size or terms of the public offering and private placement. All shares in the public offering and private placement are to be sold by ContraFect.  

ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc.

Primary Endpoint of Clinical Response at Day 14 in Patients with    Methicillin-Resistant Staph aureus    (   MRSA) Bacteremia, including Right-Sided Endocarditis

ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA

YONKERS, N.Y., Sept.  26, 2019  (GLOBE NEWSWIRE) --   ContraFect Corporation    (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that the Company has been selected to give a Late Breaker oral presentation on the reduction in health resource utilization among methicillin-resistant Staphylococcus aureus (MRSA) patients treated with exebacase in the recently completed Phase 2 study of exebacase at ID Week 2019, October 2-6, in Washington, DC. The company will also present the results of antimicrobial susceptibility testing of Staph aureus isolates from the Phase 2 clinical study, as well as the results of several preclinical efficacy studies, which further advance the understanding of activity of exebacase against biofilms and in infective endocarditis.

ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019

YONKERS, New York, Sept.  04, 2019  (GLOBE NEWSWIRE) --   ContraFect Corporation    (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as a new modality for the treatment of life-threatening, antibiotic-resistant infections, today announced that Roger J. Pomerantz, MD, Chairman and Chief Executive Officer, will present at the 2019 Janney Montgomery Scott Healthcare Conference on Tuesday, September 10, 2019, at 9:05 a.m. ET in New York City. The focus will be on exebacase (CF-301), the Company's novel therapeutic candidate for Staph aureus bacteremia, including endocarditis, along with an update on the progress of its other pipeline assets.

ContraFect to Present at the 2019 Janney Healthcare Conference

YONKERS, N.Y., Aug.  28, 2019  (GLOBE NEWSWIRE) --   ContraFect Corporation    (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as a new modality for the treatment of life-threatening, antibiotic-resistant infections, today announced the company’s poster presentation of results from an ex vivo study of its amurin peptide candidate, Aap2-M1, at the jointly sponsored American Society of Microbiology and European Society of Clinical Microbiology and Infectious Disease (ASM/ESCMID) Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, to be held from September 3-6, 2019, in Boston. In this study, a clinically relevant concentration of Aap2-M1 eradicated Stenotrophomonas biofilms formed inside hemodialysis catheters removed from patients with suspected catheter-related bloodstream infections in the clinical care setting. Stenotrophomonas is an opportunistic, multidrug-resistant, Gram-negative pathogen, which is associated with high morbidity and mortality in hospitalized patients, particularly immunocompromised and debilitated individuals, and is a recognized pathogen for cystic fibrosis patients. These new data provide the first evidence of the activity of an amurin peptide against biofilm formed by a deadly Gram-negative pathogen in the setting of human infection. 

ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

News for ContraFect Stock (CFRX)